- Home
- FEDU vs INAB Comparison
FEDU vs INAB Comparison
Compare FEDU & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- INAB
- Stock Information
- Founded
- FEDU 2007
- INAB 2016
- Country
- FEDU China
- INAB United States
- Employees
- FEDU N/A
- INAB N/A
- Industry
- FEDU
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- INAB Health Care
- Exchange
- FEDU NYSE
- INAB Nasdaq
- Market Cap
- FEDU 22.7M
- INAB 23.5M
- IPO Year
- FEDU 2017
- INAB 2021
- Fundamental
- Price
- FEDU $10.96
- INAB $0.34
- Analyst Decision
- FEDU
- INAB Strong Buy
- Analyst Count
- FEDU 0
- INAB 3
- Target Price
- FEDU N/A
- INAB $7.75
- AVG Volume (30 Days)
- FEDU 3.2K
- INAB 2.6M
- Earning Date
- FEDU 11-29-2024
- INAB 11-12-2024
- Dividend Yield
- FEDU 20.98%
- INAB N/A
- EPS Growth
- FEDU N/A
- INAB N/A
- EPS
- FEDU 0.29
- INAB N/A
- Revenue
- FEDU $17,447,877.00
- INAB N/A
- Revenue This Year
- FEDU N/A
- INAB N/A
- Revenue Next Year
- FEDU N/A
- INAB N/A
- P/E Ratio
- FEDU $37.53
- INAB N/A
- Revenue Growth
- FEDU 266.63
- INAB N/A
- 52 Week Low
- FEDU $7.41
- INAB $0.22
- 52 Week High
- FEDU $22.70
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- FEDU 39.68
- INAB 52.90
- Support Level
- FEDU $11.04
- INAB $0.30
- Resistance Level
- FEDU $12.48
- INAB $0.37
- Average True Range (ATR)
- FEDU 0.52
- INAB 0.05
- MACD
- FEDU -0.06
- INAB 0.00
- Stochastic Oscillator
- FEDU 9.64
- INAB 49.53
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.